Association of <i>KDR</i> mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.
Yanan Cui, Pengpeng Zhang, Xiaowen Liang, Jiali Xu, Xinyin Liu, Yuemin Wu, Junling Zhang, Wei Wang, Fang Zhang, Renhua Guo
Abstract
mutations may be potential positive predictors for pan-cancer received ICIs.
Topics & Concepts
MedicineOncologyInternal medicineCancerMutationImmunotherapyImmune systemImmune checkpointCohortLung cancerCancer researchGeneImmunologyBiologyGeneticsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosisLung Cancer Treatments and Mutations